Article Text

Download PDFPDF
Machine learning in cardiovascular medicine: are we there yet?

Footnotes

  • Contributors PPS and JTD planned the outline of the article. KS, KWJ and BSG conducted the empirical analyses and literature survey, and compiled the figures. All authors contributed to the manuscript writing and editing.

  • Funding KS, KWJ, BSG and JTD acknowledge support from the National Institutes of Health: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, grant number R01-DK098242-03); National Cancer Institute (NCI, grant number U54-CA189201-02); Illuminating the Druggable Genome (IDG); Knowledge Management Center sponsored by NIH Common Fund; National Center for Advancing Translational Sciences (NCATS, grant number UL1TR000067); and Clinical and Translational Science Awards (CTSA) grant.

  • Competing interests PPS is a consultant for TeleHealthRobotics, HeartSciences and Hitachi-Aloka. JTD has received consulting fees or honoraria from Janssen Pharmaceuticals, GlaxoSmithKline, AstraZeneca and Hoffman-La Roche. JTD is a scientific advisor to LAM Therapeutics and holds equity in NuMedii, Ayasdi and Ontomics. KS has received consulting fees or honoraria from Philips Healthcare, Google, LEK Consulting and Parthenon-EY. All other authors declare no competing interests.

  • Provenance and peer review Commissioned; externally peer reviewed.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors PPS and JTD planned the outline of the article. KS, KWJ and BSG conducted the empirical analyses and literature survey, and compiled the figures. All authors contributed to the manuscript writing and editing.

  • Funding KS, KWJ, BSG and JTD acknowledge support from the National Institutes of Health: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, grant number R01-DK098242-03); National Cancer Institute (NCI, grant number U54-CA189201-02); Illuminating the Druggable Genome (IDG); Knowledge Management Center sponsored by NIH Common Fund; National Center for Advancing Translational Sciences (NCATS, grant number UL1TR000067); and Clinical and Translational Science Awards (CTSA) grant.

  • Competing interests PPS is a consultant for TeleHealthRobotics, HeartSciences and Hitachi-Aloka. JTD has received consulting fees or honoraria from Janssen Pharmaceuticals, GlaxoSmithKline, AstraZeneca and Hoffman-La Roche. JTD is a scientific advisor to LAM Therapeutics and holds equity in NuMedii, Ayasdi and Ontomics. KS has received consulting fees or honoraria from Philips Healthcare, Google, LEK Consulting and Parthenon-EY. All other authors declare no competing interests.

  • Provenance and peer review Commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles